Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Dutriaux, Caroline"'
Autor:
Saiag P; University of Paris-Saclay, UVSQ, EA4340, Boulogne-Billancourt 92100, France; APHP Hôpital Ambroise Paré, Department of Dermatology, F 92100, Boulogne-Billancourt, France. Electronic address: philippe.saiag@uvsq.fr., Robert C; Department of Dermatology, Institut Gustave Roussy, Villejuif, France., Grob JJ; Department of Dermatology, Aix-Marseille University, APHM, University Hospital Timone, Marseille, France., Mortier L; Université de Lille, INSERM U 1189, Service de Dermatologie, CHU Lille, Lille 59000, France., Dereure O; Department of Dermatology, CHU Montpellier, Montpellier, France., Lebbe C; Université de Paris, INSERM U976, Team 1, HIPI, Paris 75010, France; AP-HP Hopital Saint Louis, Service de Dermatologie, Paris 75010, France., Mansard S; Department of Dermatology, CHU Estaing, Clermont-Ferrand, France., Grange F; Department of Dermatology, CHU Reims, Reims, France., Neidhardt EM; Department of Medical Oncology, Centre Léon Bérard, Lyon, France., Lesimple T; Department of Medical Oncology, Eugene Marquis Center, Rennes, France., Machet L; Department of Dermatology, CHRU de Tours et Université François Rabelais de Tours, Tours, France., Bedane C; Department of Dermatology, CHU Limoges, Limoges, France., Maillard H; Department of Dermatology, CHRU de Tours et Université François Rabelais de Tours, Tours, France., Dalac-Rat S; Department of Dermatology, CHU Le Mans, Le Mans, France., Nardin C; Department of Dermatology, CHU Dijon, Dijon, France., Szenik A; Department of Dermatology, CHU de Besançon, Besançon, France., Denden A; Department of Medical Oncology, Novartis Pharma S.A.S.-France, Rueil-Malmaison, France., Dutriaux C; Department of Dermatology, CHU Bordeaux Hôpital St. André, Bordeaux, France.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Sep; Vol. 154, pp. 57-65. Date of Electronic Publication: 2021 Jul 06.
Autor:
Schadendorf D; Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany. Electronic address: dirk.schadendorf@uk-essen.de., Hauschild A; University Hospital Schleswig-Holstein, Kiel, Germany., Santinami M; Fondazione Istituto Nazionale Tumori, Milan, Italy., Atkinson V; Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, QLD, Australia., Mandalà M; Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy., Chiarion-Sileni V; Melanoma Oncology Unit, Veneto Oncology Institute-IRCCS, Padova, Italy., Larkin J; Royal Marsden NHS Foundation Trust, London, UK., Nyakas M; Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway., Dutriaux C; Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France., Haydon A; The Alfred Hospital, Melbourne, VIC, Australia., Robert C; Institute Gustave Roussy, Paris, France., Mortier L; Université de Lille, INSERM U 1189, Lille, France., Lesimple T; Medical Oncology Department, Centre Eugène Marquis, Rennes, France., Plummer R; Northern Centre for Cancer Care, Freeman Hospital and Newcastle University, Newcastle upon Tyne, UK., Schachter J; Ella Lemelbaum Institute for Immuno-Oncology and Melanoma, Sheba Medical Center, Tel Hashomer, Israel; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel., Dasgupta K; Novartis Healthcare, Hyderabad, India., Manson S; Novartis Pharmaceuticals, East Hanover, NJ, USA., Koruth R; Novartis Pharmaceuticals, East Hanover, NJ, USA., Mookerjee B; Novartis Pharmaceuticals, East Hanover, NJ, USA., Kefford R; Macquarie University, Sydney, NSW, Australia; Melanoma Institute Australia, Sydney, NSW, Australia; Westmead Hospital, Sydney, NSW, Australia; The University of Sydney, Sydney, NSW, Australia., Dummer R; University Hospital Zürich Skin Cancer Center, Zürich, Switzerland., Kirkwood JM; Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA., Long GV; Melanoma Institute Australia, Sydney, NSW, Australia; The University of Sydney, Sydney, NSW, Australia; Royal North Shore Hospital, Sydney, NSW, Australia; Mater Hospital, Sydney, NSW, Australia.
Publikováno v:
The Lancet. Oncology [Lancet Oncol] 2019 May; Vol. 20 (5), pp. 701-710. Date of Electronic Publication: 2019 Mar 27.
Autor:
Dummer R; Department of Dermatology, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland. Electronic address: reinhard.dummer@usz.ch., Ascierto PA; Melanoma Unit, Cancer Immunotherapy and Innovative Therapies, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy., Gogas HJ; Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon Hospital, Athens, Greece., Arance A; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain., Mandala M; Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy., Liszkay G; Department of Dermatology, National Institute of Oncology, Budapest, Hungary., Garbe C; Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany., Schadendorf D; Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany., Krajsova I; Department of Dermato-oncology, University Hospital Prague and Charles University First Medical Faculty, Prague, Czech Republic., Gutzmer R; Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany., Chiarion Sileni V; Melanoma Cancer Unit, Oncology Institute of Veneto IRCCS, Padua, Italy., Dutriaux C; Department of Oncologic Dermatology, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux Cédex, France., de Groot JWB; Department of Medical Oncology, Isala, Zwolle, Netherlands., Yamazaki N; Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan., Loquai C; Department of Dermatology, University Medical Center Mainz, Mainz, Germany., Moutouh-de Parseval LA; Translational Clinical Oncology, Novartis Pharma AG, Basel, Switzerland., Pickard MD; Array BioPharma, Boulder, CO, USA., Sandor V; Array BioPharma, Boulder, CO, USA., Robert C; Service of Dermatology, Department of Medicine and Paris-Sud University, Gustave Roussy, Villejuif Cedex, France., Flaherty KT; Cancer Center, Massachusetts General Hospital, Boston, MA, USA.
Publikováno v:
The Lancet. Oncology [Lancet Oncol] 2018 Oct; Vol. 19 (10), pp. 1315-1327. Date of Electronic Publication: 2018 Sep 12.
Autor:
Dummer R; Department of Dermatology, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland. Electronic address: reinhard.dummer@usz.ch., Ascierto PA; Melanoma Unit, Cancer Immunotherapy and Innovative Therapies, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy., Gogas HJ; Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon Hospital, Athens, Greece., Arance A; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain., Mandala M; Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy., Liszkay G; Department of Dermatology, National Institute of Oncology, Budapest, Hungary., Garbe C; Department of Dermatology, University Hospital Tüebingen, Tüebingen, Germany., Schadendorf D; Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany., Krajsova I; Department of Dermato-oncology, University Hospital Prague, Charles University First Medical Faculty, Prague, Czech Republic., Gutzmer R; Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany., Chiarion-Sileni V; Melanoma Cancer Unit, Oncology Institute of Veneto IRCCS, Padua, Italy., Dutriaux C; Department of Oncologic Dermatology, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France., de Groot JWB; Department of Medical Oncology, Isala, Zwolle, Netherlands., Yamazaki N; Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan., Loquai C; Department of Dermatology, University Medical Center Mainz, Mainz, Germany., Moutouh-de Parseval LA; Translational Clinical Oncology, Novartis Pharma AG, Basel, Switzerland., Pickard MD; Array BioPharma, Boulder, CO, USA., Sandor V; Array BioPharma, Boulder, CO, USA., Robert C; Service of Dermatology, Department of Medicine, Paris-Sud University, Gustave Roussy, Villejuif, France., Flaherty KT; Cancer Center, Massachusetts General Hospital, Boston, MA, USA.
Publikováno v:
The Lancet. Oncology [Lancet Oncol] 2018 May; Vol. 19 (5), pp. 603-615. Date of Electronic Publication: 2018 Mar 21.
Autor:
Dréno B; Department of Dermato Cancerology, Nantes University, Nantes 44093, France., Ascierto PA; Istituto Nazionale Tumori Fondazione G. Pascale, Naples 80131, Italy., Atkinson V; Princess Alexandra Hospital, Woolloongabba, QLD 4102, Australia., Liszkay G; National Institute of Oncology, Budapest 1122, Hungary., Maio M; Azienda Ospedaliera Universitaria Senese, Siena 53100, Italy., Mandalà M; Department of Oncology and Haematology, Papa Giovanni XXIII Hospital, Bergamo 24127, Italy., Demidov L; N. N. Blokhin Russian Cancer Research Center, Moscow 115478, Russia., Stroyakovskiy D; Moscow City Oncology Hospital 62, Krasnogorsk 14301, Russia., Thomas L; Service de Dermatologie, Centre Hospitalier Lyon Sud, Pierre-Bénite 69495, France., de la Cruz-Merino L; Hospital Universitario Virgen Macarena, Seville 41009, Spain., Dutriaux C; Hôpital Saint André, Bordeaux 33075, France., Garbe C; Department of Dermatology, University of Tübingen, Tübingen 72074, Germany., Bartley K; Genentech, Inc., South San Francisco, CA 94080, USA., Karagiannis T; Genentech, Inc., South San Francisco, CA 94080, USA., Chang I; Genentech, Inc., South San Francisco, CA 94080, USA., Rooney I; Genentech, Inc., South San Francisco, CA 94080, USA., Koralek DO; Genentech, Inc., South San Francisco, CA 94080, USA., Larkin J; The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK., McArthur GA; Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia.; University of Melbourne, Parkville, VIC 3052, Australia., Ribas A; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA 90095, USA.
Publikováno v:
British journal of cancer [Br J Cancer] 2018 Mar 20; Vol. 118 (6), pp. 777-784. Date of Electronic Publication: 2018 Feb 13.
Autor:
Dummer R; Department of Dermatology, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland. Electronic address: reinhard.dummer@usz.ch., Schadendorf D; Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany., Ascierto PA; Melanoma Unit, Cancer Immunotherapy and Innovative Therapies, Istituto Nazionale Tumori Fondazione Pascale, Via Mariano Semmola, Naples, Italy., Arance A; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain., Dutriaux C; Department of Oncologic Dermatology, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France., Di Giacomo AM; Medical Oncology and Immunotherapy, University Hospital of Siena, Viale Bracci, Siena, Italy., Rutkowski P; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland., Del Vecchio M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian, Milan, Italy., Gutzmer R; Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany., Mandala M; Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy., Thomas L; Department of Dermatology, Centre Hospitalier Lyon Sud, Lyons Cancer Research Center, Lyon 1 University, Pierre Bénite, France., Demidov L; N N Blokhin Russian Cancer Research Center, Ministry of Health, Moscow, Russian Federation., Garbe C; Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany., Hogg D; Department of Medicine, University Health Network/Princess Margaret Hospital, Toronto, ON, Canada., Liszkay G; Department of Dermatology, National Institute of Oncology, Budapest, Hungary., Queirolo P; Department of Medical Oncology, Institute for Cancer Research, IRCCS San Martino, Largo Rosanna Benzi, Genova, Italy., Wasserman E; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, USA., Ford J; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, USA., Weill M; Novartis Pharma AG, Basel, Switzerland., Sirulnik LA; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, USA., Jehl V; Novartis Pharma AG, Basel, Switzerland., Bozón V; Array BioPharma, Boulder, CO, USA., Long GV; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia., Flaherty K; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA.
Publikováno v:
The Lancet. Oncology [Lancet Oncol] 2017 Apr; Vol. 18 (4), pp. 435-445. Date of Electronic Publication: 2017 Mar 09.
Autor:
Ascierto PA; Istituto Nazionale Tumori Fondazione G Pascale, Naples, Italy., McArthur GA; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; University of Melbourne, Parkville, VIC, Australia. Electronic address: grant.mcarthur@petermac.org., Dréno B; Nantes University, Nantes, France., Atkinson V; Princess Alexandra Hospital, Woolloongabba, QLD, Australia., Liszkay G; National Institute of Oncology, Budapest, Hungary., Di Giacomo AM; Azienda Ospedaliera Universitaria Senese, Siena, Italy., Mandalà M; Papa Giovanni XXIII Hospital, Bergamo, Italy., Demidov L; N N Blokhin Russian Cancer Research Center, Moscow, Russia., Stroyakovskiy D; Moscow City Oncology Hospital 62, Krasnogorsk, Russia., Thomas L; Centre Hospitalier Lyon Sud, Lyon 1 University, Lyon, France; Lyons Cancer Research Center, Lyon, France., de la Cruz-Merino L; Hospital Universitario Virgen Macarena, Seville, Spain., Dutriaux C; Hôpital Saint André, Bordeaux, France., Garbe C; University of Tübingen, Tübingen, Germany., Yan Y; Genentech Inc, South San Francisco, CA, USA., Wongchenko M; Genentech Inc, South San Francisco, CA, USA., Chang I; Genentech Inc, South San Francisco, CA, USA., Hsu JJ; Genentech Inc, South San Francisco, CA, USA., Koralek DO; Genentech Inc, South San Francisco, CA, USA., Rooney I; Genentech Inc, South San Francisco, CA, USA., Ribas A; Jonsson Comprehensive Cancer Center at University of California, Los Angeles, Los Angeles, CA, USA., Larkin J; Royal Marsden NHS Foundation Trust, London, UK.
Publikováno v:
The Lancet. Oncology [Lancet Oncol] 2016 Sep; Vol. 17 (9), pp. 1248-60. Date of Electronic Publication: 2016 Jul 30.
Autor:
Ilie M; Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France; Human Biobank BB-0033-00025, Pasteur Hospital, Nice, France., Long-Mira E; Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France., Funck-Brentano E; EA4340-Biomarqueurs en Cancérologie et Onco-Hématologie (BCOH), University of Versailles Saint-Quentin-en-Yvelines (SQY), Boulogne, France; Department of General and Oncologic Dermatology, Ambroise Paré Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Boulogne, France., Lassalle S; Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France., Butori C; Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France., Lespinet-Fabre V; Human Biobank BB-0033-00025, Pasteur Hospital, Nice, France., Bordone O; Human Biobank BB-0033-00025, Pasteur Hospital, Nice, France., Gay A; Human Biobank BB-0033-00025, Pasteur Hospital, Nice, France., Zahaf K; Human Biobank BB-0033-00025, Pasteur Hospital, Nice, France., Poissonnet G; Surgery Department, Comprehensive Cancer Center Antoine Lacassagne, Nice, France., Lacour JP; Dermatology Department, Archet II Hospital, Nice, France., Bahadoran P; Dermatology Department, Archet II Hospital, Nice, France; Institut National de la Santé et de la Recherche Médicale (INSERM) U1065, Team 1, University of Nice Sophia Antipolis, Nice, France., Ballotti R; Institut National de la Santé et de la Recherche Médicale (INSERM) U1065, Team 1, University of Nice Sophia Antipolis, Nice, France., Gros A; Pathology and Molecular Biology Departments, Centre Hospitalier Universitaire (CHU) and EA2406 University of Bordeaux, Bordeaux, France., Dutriaux C; Department of Oncologic Dermatology, CHU Bordeaux, Bordeaux, France., Saiag P; EA4340-Biomarqueurs en Cancérologie et Onco-Hématologie (BCOH), University of Versailles Saint-Quentin-en-Yvelines (SQY), Boulogne, France; Department of General and Oncologic Dermatology, Ambroise Paré Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Boulogne, France., Merlio JP; Pathology and Molecular Biology Departments, Centre Hospitalier Universitaire (CHU) and EA2406 University of Bordeaux, Bordeaux, France., Vergier B; Pathology and Molecular Biology Departments, Centre Hospitalier Universitaire (CHU) and EA2406 University of Bordeaux, Bordeaux, France., Emile JF; EA4340-Biomarqueurs en Cancérologie et Onco-Hématologie (BCOH), University of Versailles Saint-Quentin-en-Yvelines (SQY), Boulogne, France; Department of Pathology, Ambroise Paré Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Boulogne, France., Hofman V; Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France; Human Biobank BB-0033-00025, Pasteur Hospital, Nice, France., Hofman P; Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France; Human Biobank BB-0033-00025, Pasteur Hospital, Nice, France. Electronic address: hofman.p@chu-nice.fr.
Publikováno v:
Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2015 May; Vol. 72 (5), pp. 786-93. Date of Electronic Publication: 2015 Feb 07.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ascierto, Paolo A, Dréno, Brigitte, Larkin, James, Ribas, Antoni, Liszkay, Gabriella, Maio, Michele, Mandalà, Mario, Demidov, Lev, Stroyakovskiy, Daniil, Thomas, Luc, de la Cruz-Merino, Luis, Atkinson, Victoria, Dutriaux, Caroline, Garbe, Claus, Hsu, Jessie, Jones, Surai, Li, Haocheng, McKenna, Edward, Voulgari, Athina, McArthur, Grant A
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 19
PurposeThe randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and overall survival (OS) with addition of cobimetinib to vemurafenib compared with vemurafenib in patients with previously untreated BRA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::f168e6038fb340343b7c12cb56cfbffb
https://escholarship.org/uc/item/1g1197j5
https://escholarship.org/uc/item/1g1197j5